Theradiag SA (ALTER.PA)

2.3 €

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol ALTER.PA
Price 2.3 €
Beta 0.167
Volume Avg. 0.05M
Market Cap 29.954M
Shares () -
52 Week Range 1.268355-2.75
1y Target Est -
DCF Unlevered ALTER.PA DCF ->
DCF Levered ALTER.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 61.95% Buy
P/E -
P/B 3.37 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Bertrand de Castelnau
Healthcare
Medical Devices
Paris

Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.